Intravesical Therapy of Superficial Bladder T ransitional Cell Carcinoma with Tumor Necrosis Factor-Alpha: Preliminary Report of a Phase I—II Study
- 1 January 1992
- journal article
- clinical trial
- Published by Elsevier in European Urology
- Vol. 22 (2) , 112-114
- https://doi.org/10.1159/000474735
Abstract
A phase I-II trial of intravesical immunotherapy with tumor necrosis factor (TNF)-alpha in 24 patients affected by superficial bladder tumors is herein presented. Of these, 11 patients were submitted, at weekly intervals, after complete TUR, to 8 instillations of TNF-alpha at increasing doses from 50 to 600 micrograms. Tolerability was excellent, even at the highest dose. In a second group of 13 patients with a histologically proved papillary marker lesion, TNF-alpha was instilled at weekly intervals at the dose of 500 micrograms for 8 weeks. Three complete responses (23%) were obtained.Keywords
This publication has 0 references indexed in Scilit: